agreement

US Allotropic Tech and Bionaturis Group join forces

Bionaturis Group and the US-biotech company Allotropic Tech has signed an agreement to work together in the development of biological products for pharmaceutical, petrochemical, nutritional, and cosmetic industries, among others. Allotropic Tech’s personnel are pioneers in the field of expression systems in insects such as FLYLIFE. 
According to Bionaturis Group’s CEO, Victor Infante, “with this agreement, Bionaturis Group continues adding up strategic alliances and improving its competitiveness. Allotropic’s team is composed of recognized experts at using insects to express difficult to obtain proteins, and therefore, one more value added for our clients and development partners. This agreement will also allow us to broaden our product portfolio”.
Allotropic’s CEO, Robert Balcerzak, has stated “we look forward to collaborating with Bionaturis in advancing the expression of proteins in insects and are particularly excited about drawing on Bionaturis’ worldwide sales presence”.
About Allotropic
Allotropic Tech is located in Baltimore MD USA with facilities located in the mid-Atlantic corridor region. Allotropic Tech has extensive experience supplying recombinant proteins with particular emphasis on supplying proteins to government laboratories, university research departments and corporate R&D departments.
About Bionaturis

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in the vaccines research, the biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).
 

December 4th, 2015|Blog english, Sin categoría|Comments Off|

Bionaturis signs a strategic agreement for its corporate expansion in China

As part of the agreement, Bionaturis Group will establish its first subsidiary company in China in the new technological area of Changshu (Jiangsu).

The new technological and industrial area of Changshu has been the one which has relied most on hosting the Spanish biotechnological group.

Bionaturis’ system for the development of biological medicinal products, known as Flylife, will serve as a baseline for the project.

Jerez de la Frontera, July 2nd 2015. Bionaturis Group and the Administrative Committee of Changshu New & Hi-Tech Industrial Development Zone –CNZ- (Jiangsu) – have signed a strategic agreement to host a subsidiary company of the biotechnological Spanish group, which will serve to develop and allocate biotechnological products in the Asian market.

As part of the agreement, within the park Bionaturis Group will have cutting-edge facilities in order to carry out its activities, as well as a diversity of direct incentive programs. In a first phase, facilities of 600 meters squared have been set out, which include a laboratory area and an administrative one. The laboratory area will host, among other services, Bionaturis’ biological medical production system, known as Flylife, and its capacity to develop state-of-the-art vaccines for human and animal health. In the new subsidiary company, the Spanish Group will also have a development department as well as a commercial office.

Currently, Bionaturis Group develops, at different stages, a variety of medicines intended for human health, as well as veterinary products that act or prevent habitual diseases in livestock (poultry, pigs, cattle…), farmed fish and pet animals.

Victor Infante, Chief Executive of Bionaturis Group, believes that “China is and will increasingly be one of the main markets in human and animal health. The commitment of Changshu’s authorities to host Bionaturis Group is a proof […]

July 2nd, 2015|Blog english, Press Releases|Comments Off|

Bionaturis and the US-Biotech company BMI sign an agreement for the jointly development of human and animal vaccines

The goal of this strategic partnership is to join forces to bring to market new and improved biopharmeutical products.

As the first step of this agreement, Bionaturis Group will support the manufacturing development of a first-in-class vaccine to prevent the human common cold.

 

Jerez, June 18th 2015. Bionaturis Group and Biological Mimetics, Inc., -BMI- (based in Maryland, USA) has started a new strategic collaboration agreement to jointly develop new vaccines for human and animal health applications.

In the context of this agreement Bionaturis Group will use its proprietary FLYLIFE platform for the production of experimental batches of vaccines designed using BMI’s Immune Refocusing Technology (IRT). Specifically, as part of the agreement, Bionaturis Group has begun the works corresponding to the manufacturing proof of concept of a candidate of BMI of a first in man vaccine against Human Rhinovirus, the cause of the common cold as well as primary infant viral pneumonia and its known associations with asthma.

According to the National Center of Health, in the United States there are around 62 million cases annually of common cold with human rhinovirus infection being the culprit for about 35% of them. There are over 100 different types of rhinoviruses, which makes developing a vaccine against rhinoviruses difficult. According to experts, the economic consequences of absenteeism from work, school and primary care services caused by the common cold have an impact, only in the United States economy, between 35 and 40 billion US dollars a year.

The lead of BMI is designed to become the first in man cross serotype vaccine on the market to prevent and/or limit clinical complications from infection. The vaccine is to undergo preclinical and process development and evaluation, carrying out safety, immunogenicity and efficacy trials using […]

June 18th, 2015|Blog english, Press Releases|Comments Off|

Roche and Oryzon, a historic agreement for Spanish Biotechnology

Roche has bought the rights to an experimental drug from Spain’s Oryzon Genomics that can switch on genes to block cancer growth, as the Swiss drugmaker looks to maintain its dominance in the lucrative field of oncology. The world’s largest maker of cancer drugs will pay Barcelona-based Oryzon $21 million in upfront and near-term milestone payments and could pay out more than $500 million if the company meets other goals. The deal will give Roche rights to Oryzon’s experimental drug ORY-1001 which was granted orphan drug status by European health regulators last year and is currently in early-stage clinical testing for acute myeloid leukaemia. Roche will also pay up to mid-double digit percentage royalties if the drug makes it to market.

ORY-1001 works by blocking an enzyme called Lysine Specific Demethylase 1 (LSD1), which turns off genes and has been identified as playing a role in certain types of leukaemia.The deal includes a two-year collaboration to develop LSD1 inhibitors at Roche’s Translational Clinical Research Centre in New York.

From all the Bionaturis´ team, just to say congratulations to our colleagues of Oryzon and the best wishes for the hard work ahead with Roche!

April 9th, 2014|Blog english|0 Comments|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR